NASDAQ:EYES - Second Sight Medical Products Stock Price, News, Headlines & Rumors

Second Sight Medical Products trades on the NASDAQ under the ticker symbol "EYES."

Second Sight Medical Products Inc (NASDAQ:EYES) issued its quarterly earnings results on Tuesday, August, 7th. The medical device company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.02. The medical device company had revenue of $1.91 million for the quarter, compared to analysts' expectations of $2.21 million. Second Sight Medical Products had a negative return on equity of 432.45% and a negative net margin of 418.82%. View Second Sight Medical Products' Earnings History.

Second Sight Medical Products is scheduled to release their next quarterly earnings announcement on Thursday, November, 1st 2018. View Earnings Estimates for Second Sight Medical Products.

1 analysts have issued twelve-month price objectives for Second Sight Medical Products' shares. Their predictions range from $5.00 to $5.00. On average, they anticipate Second Sight Medical Products' stock price to reach $5.00 in the next year. This suggests a possible upside of 231.1% from the stock's current price. View Analyst Price Targets for Second Sight Medical Products.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Second Sight Medical Products in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Second Sight Medical Products.

Some companies that are related to Second Sight Medical Products include electroCore (ECOR), BioLife Solutions (BLFS), Rockwell Medical (RMTI), Vision Sciences (CGNT), Helius Medical Technologies (HSDT), Fonar (FONR), Semler Scientific (SMLR), Zynex Inc. common stock (ZYXI), IRIDEX (IRIX), BioSig Technologies (BSGM), Edap Tms (EDAP), Viveve Medical (VIVE), Soleno Therapeutics (SLNO), Stereotaxis (STXS) and Digirad (DRAD).

(EYES) raised $32 million in an initial public offering (IPO) on Wednesday, November 19th 2014. The company issued 3,500,000 shares at a price of $9.00 per share. MDB Capital Group, LLC served as the underwriter for the IPO.

Media stories about EYES stock have trended somewhat positive recently, according to Accern Sentiment. The research firm rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Second Sight Medical Products earned a news impact score of 0.09 on Accern's scale. They also gave media stories about the medical device company an impact score of 47.04 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. View Recent Headlines for Second Sight Medical Products.

Shares of EYES can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of EYES stock can currently be purchased for approximately $1.51.

Second Sight Medical Products has a market capitalization of $107.99 million and generates $7.96 million in revenue each year. The medical device company earns $-28,510,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. Second Sight Medical Products employs 112 workers across the globe.

Second Sight Medical Products' mailing address is 12744 SAN FERNANDO ROAD SUITE 400, SYLMAR CA, 91342. The medical device company can be reached via phone at 818-833-5000 or via email at [email protected]